ixed chimerism is a promising approach toward generating donor-specific immunological tolerance. However, chimerism induction can be toxic; therefore, there is an effort to develop non-myeloablative, minimal intensity protocols that can generate chimerism without the toxic side effects. Recently, with the goal of creating a minimalistic chimerism induction protocol in the tolerance resistant non-obese diabetic (NOD) mouse model, we identified pre-existing T cells as cells that resist fully allogeneic chimerism. With monoclonals targeting NOD T cells, we showed that long-term chimerism and tolerance toward donor islets could be established. However, this promising new protocol relied on the administration of a single dose of anti-CD40 ligand, which is not clinically applicable. In refining protocols to move even closer to clinical utility, we report here initial success at generating fully allogeneic mixed chimerism in NOD mice by adding cyclophosphamide to the conditioning regimen in place of anti-CD40 ligand antibodies.
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The generation of mixed hematopoietic chimerism in transplant recipients has the potential to generate donor specific tolerance, thereby eliminating both rejection episodes and the need for immunosuppressive medications. 1, 2 In the clinical setting, generating mixed chimerism is in its infancy and induction protocols are being constantly revised. [1] [2] [3] As such, chimerism induction protocols developed in experimental animal systems should be We identified the barrier that pre-existing T cells impose both on the induction of mixed chimerism and the ability of mixed chimerism to generate donor-specific tolerance across full major and minor histocompatibility barriers. 4 After identifying the pre-existing T cell barrier, we developed a nonmyeloablative (irradiation free) chimerism induction protocol based on antibodies targeting NOD T cells that was able to generate long-term mixed chimerism. In brief, the protocol included preconditioning with antibodies against CD4 and CD8, a single dose of both busulfan (day -1) and anti-CD40L (day 0), bone marrow transplantation (BMT; day 0), and a short course of rapamycin (day 0-28). These chimeric NOD mice mice, with one mouse losing chimerism completely (Fig. 1B) . At approximately 10 weeks post-chimerism induction, we challenged the three chimeric mice with a C3H islet transplant. The mouse with the highest levels of chimerism and the mouse that eventually lost chimerism accepted donor islets for greater than 100 days and returned to hyperglycemia after the islet graft-bearing kidney was removed (data not shown). Despite the maintenance of chimerism, the mouse with an intermediate level of chimerism rejected donor islets at day 23 post-islet transplant. This demonstration of split tolerance in C3H→NOD mixed chimeras is consistent with our previous results. 4, 17 Since higher doses of CYP can be used to induce diabetes in NOD mice, 15 it is important to note none of the mice in these experiments developed spontaneous diabetes (data not shown).
The combination of CYP and rapamycin may be an especially interesting strategy for chimerism induction because it combines the ability of CYP to deplete alloreactive lymphocytes 14 with the antiproliferative and regulatory T cell promoting effects of rapamycin. 18, 19 Indeed, the combination of these two agents has recently been shown to promote stable chimerism in a BALB/c→C57BL/6 model (personal communication Jonathan D. Powell, manuscript submitted). However, in the current experiments with NOD mice, antibodies targeting T cells were required in addition to CYP and rapamycin in order to generate allogeneic chimerism. The additional T cell targeting required is likely due to the tolerance resistance of NOD mice. [20] [21] [22] In these preliminary studies, we have found that a lymphocyte depletion protocol that includes CYP (and completely avoids anti-CD40L) is indeed capable of generating fully allogeneic mixed chimeras in NOD mice. While a promising beginning, it will be important to determine if further optimization of this anti-CD40L free protocol will allow stable levels of mixed chimerism. Furthermore, it will be important to examine whether successful CYP-based chimerism induction protocols in pre-diabetic NOD mice are effective in generating chimerism and tolerance after the onset of spontaneous were immunocompetent, diabetes free and could accept donor islet allografts.
Although many aspects of the successful chimerism induction protocols we developed in NOD mice are clinically translatable, they remain protocols that require anti-CD40 ligand (anti-CD40L). 4 Since anti-CD40L is not available for clinical use, 5 we began testing whether anti-CD40L can be replaced with cyclophosphamide (CYP). CYP is an alkylating agent used clinically for the treatment of leukemia, lymphoma, 6 and in some cases as an induction agent for lupus nephritis. 7 More recently, CYP has been used as an agent to prevent graft-vs.-host disease (GVHD) after BMT. 3, 8 Previously, CYP has been used quite extensively in both solid organ and cellular transplantation experiments in mice. [9] [10] [11] [12] Focusing specifically on BMT, CYP has been used most commonly in combination with total body irradiation (TBI) and T cell depleting antibodies. These studies have shown that CYP can increase the level of chimerism when combined with T cell depleting antibodies and can decrease the amount of TBI required to establish chimerism in B10.BR to B10 chimeras. 13 The mechanism of CYP action is thought to be mainly through the destruction of donorreactive T cells. 14 In relation to NOD mice, previous studies have shown that the administration of a high dose of CYP (200 mg/kg) leads to the rapid, synchronous development of diabetes 15 via a mechanism thought to be dependent on reduced regulatory T cell function. 16 However, to our knowledge, CYP has not been tested in the difficult NOD mouse model as an agent for chimerism induction. Therefore, our aim was to determine if inclusion of CYP as an agent to induce chimerism in NOD mice would obviate the need for anti-CD40L.
We attempted three different protocols that included CYP (150 mg/kg) as part of the conditioning regimen to induce chimerism in pre-diabetic NOD mice using fully allogeneic C3H donor bone marrow (Fig. 1 legend) . Protocols 1 and 2 were unsuccessful at chimerism induction, however, protocol 3 was successful at inducing chimerism in 3/5 mice (Fig. 1A) . Over time, the level of donor chimerism declined in all three of these 6 unmodified C3H BMCs into nOd mice was performed as part of one of three different non-myeloablative protocols that included the i.p. administration CYP at 150mg/kg body weight. Protocol 1: CYP and nK depletion. CYP was administered on day +2 relative to BMt and rapamycin at 3 mg/kg was administered i.p. daily from day +4 to +28. Protocol 2: CYP, nK depletion and donor specific transfusion (dSt). recipient nOd mice were given a dSt of 20 × 10 6 unmodified C3H spleen cells i.v. on day -4. CYP was administered on day -2 and rapamycin was given daily from day 0 to +28. Protocol 3: CYP, nK and t cell depletion. On day -3, t cell depletion was performed by administering anti-Cd4 (GK1.5) and anti-Cd8 (53.6.7). CYP was administered on day +2 and rapamycin was given daily from day +4 to +28. diabetes. Although the C3H chimerism levels declined in all three chimeric mice, and was completely lost in one case, it is exciting to see that two of these NOD chimeras accepted donor islets. Fully allogeneic chimeric NOD mice have a tendency to develop split tolerance and it will be important in future studies to determine the degree of split tolerance that develops in mice made chimeric with CYP as part of their induction protocol. In addition, mechanistic studies of lymphocyte function in the setting of rapamycin together with anti-CD40L vs. CYP are needed to elucidate the potential of CYP to replace targeting of CD40L.
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